0
0
May 3, 2025 – A landmark clinical trial has confirmed that a significantly shorter course of radiotherapy is just as safe and effective as the traditional eight-week schedule for men with localized prostate cancer-even a decade after treatment. The findings, presented at the ESTRO 2025 Congress (European Society for Radiotherapy and Oncology), offer new hope for patients and could transform standard cancer care worldwide.
Shorter, Effective, and Patient-Friendly
Prostate cancer remains the most commonly diagnosed cancer in men globally, with over 1.4 million new cases annually. Radiotherapy is a cornerstone of treatment, but the conventional approach typically requires daily sessions over several weeks. This can disrupt patients’ lives and strain healthcare resources.
The HYPO-RT-PC trial, led by Swedish researchers at Skåne University Hospital and Lund University, investigated whether a condensed, two-and-a-half-week course of radiotherapy-known as “ultra hypo-fractionated radiotherapy”-could match the effectiveness and safety of the standard eight-week regimen.
Study Details and Results
The phase III trial enrolled 1,200 men with intermediate- to high-risk localized prostate cancer. Participants were randomly assigned to receive either:
-
Short-course radiotherapy: 42.7 Gray (Gy) in 7 sessions over 2.5 weeks
-
Standard-course radiotherapy: 78.0 Gy in 39 sessions over 8 weeks
After 10 years, the results were strikingly similar:
-
Failure-free survival: 72% (short-course) vs 65% (standard)
-
Overall survival: 81% (short-course) vs 79% (standard)
-
Prostate cancer-specific mortality: 4% in both groups
-
Side effects: Urinary and bowel symptoms were comparable and mostly mild to moderate
“These long-term findings confirm previous five-year results, showing that delivering fewer, higher doses over a shorter period works just as well as the standard approach-not just in theory, but in real-world clinical practice,” said Associate Professors Per Nilsson and Adalsteinn Gunnlaugsson, the study’s lead investigators.
Implications for Patients and Healthcare
The study’s outcomes suggest that men can undergo effective prostate cancer treatment with far less disruption to their daily lives and potentially lower healthcare costs. “Reducing treatment time to just two and a half weeks is a major win for both patients and health systems,” said Professor Matthias Guckenberger, President of ESTRO.
Experts believe these results may soon influence treatment guidelines, making cancer care more efficient, accessible, and patient-friendly-without sacrificing effectiveness or safety.
Disclaimer:
This article is based on findings presented at the ESTRO 2025 Congress and published by News-Medical.net. The information is intended for general informational purposes only and should not be considered medical advice. Patients should consult their healthcare providers before making any decisions about cancer treatment.
Citations:
